至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Evaluation of combination vaccines targeting transmission of Plasmodium falciparum and P. vivax

Vaccine. 2024-07; 
Yi Cao 1, Clifford T H Hayashi , Maisa da Silva Araujo , Abhai K Tripathi , Alice Oliveira Andrade , Jansen Fernandes Medeiros , Joseph Vinetz & Nirbhay Kumar
Products/Services Used Details Operation
Codon Optimization The DNA sequences encoding Pvs25 (Salvador I strain, PlasmoDB accession: PVX_111175, aa 23–195) , Pfs25 (3D7 strain, AF193769.1, aa 18–202) , Pvs48/45 (Salvador I strain, PlasmoDB accession: PVX_083235, aa 28–426), and Pfs48/45 (3D7 strain, PlasmoDB accession:PF3D7_1346700, aa 28–427) , all lacking N-terminal signal and C-terminal anchor sequences, were codon-optimized for mammalian expression and cloned (GenScript, NJ) into the DNA vector VR1020 (Vical, CA). Get A Quote

摘要

Transmission-blocking vaccines interrupting malaria transmission within mosquitoes represent an ideal public health tool to eliminate malaria at the population level. Plasmodium falciparum and P. vivax account for more than 90% of the global malaria burden, co-endemic in many regions of the world. P25 and P48/45 are two leading candidates for both species and have shown promising transmission-blocking activity in preclinical and clinical studies. However, neither of these target antigens as individual vaccines has induced complete transmission inhibition in mosquitoes. In this study, we assessed immunogenicity of combination vaccines based on P25 and P48/45 using a DNA vaccine platform to broaden vaccine specif... More

关键词

Combination DNA vaccines; Malaria; Plasmodium falciparum; Plasmodium vivax; Transmission-blocking antigens